Helmut U Klein

List of Publications by Year
in descending order

66	17,318	186265	149698
papers	citations	28 h-index	56 g-index

71	71	71	8136
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Advances in Our Clinical Understanding of Autonomic Regulation Therapy Using Vagal Nerve Stimulation in Patients Living With Heart Failure. Frontiers in Physiology, 2022, 13, 857538.	2.8	9
2	Sex Differences in the Risk of First and Recurrent Ventricular Tachyarrhythmias Among Patients Receiving an Implantable Cardioverter-Defibrillator for Primary Prevention. JAMA Network Open, 2022, 5, e2217153.	5.9	6
3	Protected risk stratification with the wearable cardioverter-defibrillator: results from the WEARIT-II-EUROPE registry. Clinical Research in Cardiology, 2021, 110, 102-113.	3.3	13
4	Predicted benefit of an implantable cardioverter-defibrillator: the MADIT-ICD benefit score. European Heart Journal, 2021, 42, 1676-1684.	2.2	61
5	Cardiac resynchronization therapy with- or without defibrillator. Estimating the risk of arrhythmic death or assessing the likelihood of non-arrhythmic mortality?. International Journal of Cardiology, 2021, 330, 82-83.	1.7	0
6	All for one and one for All? â€“ Do we need a VT network?. IJC Heart and Vasculature, 2021, 34, 100769.	1.1	0
7	Elective DC cardioversion of atrial fibrillation: did we use the right procedure?. European Heart Journal, 2020, 41, 632-633.	2.2	1
8	Comparison of symptomatic and functional responses to vagus nerve stimulation in ANTHEMâ€HF, INOVATEâ€HF, and NECTARâ€HF. ESC Heart Failure, 2020, 7, 76-84.	3.1	41
9	Diabetes Mellitus. JACC: Clinical Electrophysiology, 2020, 6, 559-561.	3.2	2
10	Death with an implantable cardioverter-defibrillator: a MADIT-II substudy. Europace, 2019, 21, 1843-1850.	1.7	5
11	Impact of Autonomic Regulation Therapy in Patients with Heart Failure. Circulation: Heart Failure, 2019, 12, e005879.	3.9	50
12	Considering the Need to Expand the Indications for Wearable Defibrillator Therapy. Journal of Innovations in Cardiac Rhythm Management, 2019, 10, 3751-3760.	0.5	0
13	Comparison of Long-Term Survival Benefits With Cardiac Resynchronization Therapy in Patients With Mild Heart Failure With Versus Without Diabetes Mellitus (from the Multicenter Automatic) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T Journal of Cardiology, 2018, 121, 1567-1574.	2.6	5
14	Right ventricular lead location, right-left ventricular lead interaction, and long-term outcomes in cardiac resynchronization therapy patients. Journal of Interventional Cardiac Electrophysiology, 2018, 52, 185-194.	1.3	3
15	Left Ventricular Lead Location and Long-Term Outcomes in Cardiac Resynchronization Therapy Patients. JACC: Clinical Electrophysiology, 2018, 4, 1410-1420.	3.2	20
16	Experience with the wearable cardioverter-defibrillator in older patients: Results from the Prospective Registry of Patients Using the Wearable Cardioverter-Defibrillator. Heart Rhythm, 2018, 15, 1379-1386.	0.7	11
17	Coronary revascularization: A useful antiarrhythmic approach?. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 780-782.	1.2	0
18	Do we need the wearable cardioverter-defibrillator (WCD)?. International Journal of Cardiology, 2018, 268, 151-152.	1.7	0

#	Article	IF	Citations
19	Oneâ€year followâ€up of the prospective registry of patients using the wearable defibrillator (WEARITâ€II) Tj ETQq1 1 0.784314 rgBT /C	1.2	15
20	Arthur Jay Moss MD PhD. European Heart Journal, 2018, 39, 1872-1874.	2.2	0
21	Extended use of the wearable cardioverter-defibrillator in patients at risk for sudden cardiac death. Europace, 2018, 20, f225-f232.	1.7	13
22	Rationale and design of the BUDAPEST-CRT Upgrade Study: a prospective, randomized, multicentre clinical trial. Europace, 2017, 19, euw193.	1.7	17
23	Safety of the Wearable Cardioverter Defibrillator (WCD) in Patients with Implanted Pacemakers. PACE - Pacing and Clinical Electrophysiology, 2017, 40, 271-277.	1.2	10
24	Discrepancies in the U.S. and European guidelines involving the implantable cardioverterâ€“defibrillator and cardiac resynchronization therapy: Need for a single shared international publication. Heart Rhythm, 2017, 14, 474-475.	0.7	1
25	The impact of body mass index on the wearable cardioverter defibrillator shock efficacy and patient wear time. American Heart Journal, 2017, 186, 111-117.	2.7	7
26	Multicenter Automatic Defibrillator Implantation Trialâ€“Subcutaneous Implantable Cardioverter Defibrillator (MADIT S-ICD): Design and clinical protocol. American Heart Journal, 2017, 189, 158-166.	2.7	31
27	Long-term vagal stimulation for heart failure: Eighteen month results from the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) trial. International Journal of Cardiology, 2017, 244, 229-234.	1.7	113
28	The wearable cardioverter-defibrillator: current technology and evolving indications. Europace, 2017, 19, 335-345.	1.7	65
29	Effect of Significant Weight Change on Inappropriate Implantable Cardioverterâ€Đefibrillator Therapy. PACE - Pacing and Clinical Electrophysiology, 2017, 40, 9-16.	1.2	4
30	Effect of cardiac resynchronization therapy on the risk of ventricular tachyarrhythmias in patients with chronic kidney disease. , 2017, 22, e12404.		2
31	Cost-effectiveness of implantable cardiac devices in patients with systolic heart failure. Heart, 2016, 102, 1742-1749.	2.9	30
32	Letter to the Editorâ€” Prognostic implication of baseline PR interval in patients undergoing cardiac resynchronization therapy. Heart Rhythm, 2016, 13, 1573.	0.7	0
33	No Utility of the Wearable Cardioverter-Defibrillator in Patients With Nonischemic Cardiomyopathy?. Journal of the American College of Cardiology, 2016, 67, 2807.	2.8	0
34	Sustained clinical benefit of cardiac resynchronization therapy in non-LBBB patients with prolonged PR-interval: MADIT-CRT long-term follow-up. Clinical Research in Cardiology, 2016, 105, 944-952.	3.3	41
35	Cardiac Resynchronization in Different Age Groups: A MADIT-CRT Long-Term Follow-Up Substudy. Journal of Cardiac Failure, 2016, 22, 143-149.	1.7	9
36	Apical vs. non-apical right ventricular pacing in cardiac resynchronization therapy: a meta-analysis. Europace, 2015, 17, 1259-1266.	1.7	41

#	Article	IF	Citations
37	Time-dependent risk reduction of ventricular tachyarrhythmias in cardiac resynchronization therapy patients: a MADIT-RIT sub-study. Europace, 2015, 17, 1085.1-1091.	1.7	16
38	The Effect of ICD Programming on Inappropriate and Appropriate ICD Therapies in Ischemic and Nonischemic Cardiomyopathy: The MADITâ€RIT Trial. Journal of Cardiovascular Electrophysiology, 2015, 26, 424-433.	1.7	31
39	Long-Term Outcomes With Cardiac Resynchronization Therapy in Patients With Mild Heart Failure With Moderate Renal Dysfunction. Circulation: Heart Failure, 2015, 8, 725-732.	3.9	18
40	Sex Differences in Longâ€Term Outcomes With Cardiac Resynchronization Therapy in Mild Heart Failure Patients With Left Bundle Branch Block. Journal of the American Heart Association, 2015, 4, .	3.7	37
41	Michel Mirowski and the beginning of a new era of fighting sudden arrhythmic death. Herzschrittmachertherapie Und Elektrophysiologie, 2015, 26, 61-69.	0.8	2
42	Use of the Wearable Cardioverter Defibrillator in High-Risk Cardiac Patients. Circulation, 2015, 132, 1613-1619.	1.6	199
43	Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial. European Heart Journal, 2015, 36, 425-433.	2.2	291
44	Response to Letter Regarding, â€œPR Interval Identifies Clinical Response in Patients With Non-Left Bundle Branch Block: A Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy Sub-Studyâ€•by Kutyifa et al. Circulation: Arrhythmia and Electrophysiology, 2014, 7, 1280-1280.	4.8	3
45	Risk for ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ventricular functionâ€"value of the wearable cardioverter/defibrillator. European Journal of Heart Failure, 2014, 16, 1331-1336.	7.1	121
46	Rationale and study design of the <scp>NEuroCardiac TherApy foR</scp> Heart Failure Study: <scp>NECTARâ€HF</scp>. European Journal of Heart Failure, 2014, 16, 692-699.	7.1	56
47	A Metric for Evaluating the Cardiac Response to ResynchronizationÂTherapy. American Journal of Cardiology, 2014, 113, 1371-1377.	1.6	11
48	Mortality Reduction in Relation to Implantable Cardioverter Defibrillator Programming in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT). Circulation: Arrhythmia and Electrophysiology, 2014, 7, 785-792.	4.8	101
49	Cardiac resynchronization therapy is associated with reductions in left atrial volume and inappropriate implantable cardioverter-defibrillator therapy in MADIT-CRT. Heart Rhythm, 2014, 11, 1001-1007.	0.7	4
50	Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator. European Heart Journal, 2013, 34, 2230-2242.	2.2	104
51	Preventive cardiac resynchronisation therapy. Heart, 2012, 98, 508-515.	2.9	0
52	Reduction in Inappropriate Therapy and Mortality through ICD Programming. New England Journal of Medicine, 2012, 367, 2275-2283.	27.0	1,186
53	Wearable Defibrillator in Congenital Structural Heart Disease and Inherited Arrhythmias. American Journal of Cardiology, 2011, 108, 1632-1638.	1.6	36
54	Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. European Heart Journal, 2011, 32, 847-855.	2.2	444

#	Article	IF	Citations
55	Cardiac Resynchronization Therapy in Asymptomatic or Mildly Symptomatic Heart Failure Patients. Current Treatment Options in Cardiovascular Medicine, 2010, 12, 431-442.	0.9	2
56	Bridging a Temporary High Risk of Sudden Arrhythmic Death. Experience with the Wearable Cardioverter Defibrillator (WCD). PACE - Pacing and Clinical Electrophysiology, 2010, 33, 353-367.	1.2	120
57	Vagus nerve stimulation: A new approach to reduce heart failure. Cardiology Journal, 2010, 17, 638-44.	1.2	55
58	Implantable defibrillators: 30 years of history. Giornale Italiano Di Cardiologia, 2010, 11, 48S-52S.	0.0	3
59	Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure Events. New England Journal of Medicine, 2009, 361, 1329-1338.	27.0	2,716
60	The Wearable Cardioverter Defibrillatorâ€"Bridge to the Implantable Defibrillator. Cardiac Electrophysiology Clinics, 2009, 1, 129-146.	1.7	0
61	Inappropriate Implantable Cardioverter-Defibrillator Shocks in MADIT II. Journal of the American College of Cardiology, 2008, 51, 1357-1365.	2.8	735
62	Use of a Wearable Defibrillator in Terminating Tachyarrhythmias in Patients at High Risk for Sudden Death:. Results of WEARIT/BIROAD. PACE - Pacing and Clinical Electrophysiology, 2004, 27, 4-9.	1.2	193
63	Clinical Efficacy of a Wearable Defibrillator in Acutely Terminating Episodes of Ventricular Fibrillation Using Biphasic Shocks. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 2016-2022.	1.2	69
64	Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection Fraction. New England Journal of Medicine, 2002, 346, 877-883.	27.0	6,199
65	Clinical Efficacy of the Wearable Cardioverter-Defibrillator in Acutely Terminating Episodes of Ventricular Fibrillation. American Journal of Cardiology, 1998, 81, 1253-1256.	1.6	80
66	Improved Survival with an Implanted Defibrillator in Patients with Coronary Disease at High Risk for Ventricular Arrhythmia. New England Journal of Medicine, 1996, 335, 1933-1940.	27.0	3,859